Last reviewed · How we verify
Active reference comparator
Unable to determine specific mechanism without drug identity.
At a glance
| Generic name | Active reference comparator |
|---|---|
| Sponsor | Janssen Research & Development, LLC |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
This entry refers to an 'Active reference comparator' rather than a named drug, indicating it is a control agent used in clinical trials. Without identification of the specific comparator drug, the mechanism cannot be determined.
Approved indications
Common side effects
Key clinical trials
- A Study to Evaluate the Efficacy and Safety of JNJ-77242113 (Icotrokinra) in Biologic-naïve Participants With Active Psoriatic Arthritis (PHASE3)
- Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response (PHASE3)
- Intra Oral Application (IOA) Testing Study of a Stannous Toothpaste (NA)
- Emulation of the STEP-HFpEF DM Heart Failure Trial in Healthcare Claims Data
- Emulation of the SUMMIT Heart Failure Trial in Healthcare Claims Data
- Healthier: Health Coaching for People With Rheumatoid Arthritis to Improve Mental Well-Being (NA)
- Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET (PHASE3)
- Passive Fit of Implant-Supported Complete-Arch Prostheses Using Digital Workflows (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Active reference comparator CI brief — competitive landscape report
- Active reference comparator updates RSS · CI watch RSS
- Janssen Research & Development, LLC portfolio CI